A multi‐omics approach to investigate the synapse dysfunction in Alzheimer’s disease

Abstract

AbstractBackgroundSynapse dysfunction is an early event for Alzheimer’s disease (AD) progression. Synapse dysfunctions are caused by multiple cellular and pathologic factors such as Amyloid beta, p‐tau, inflammation and aging. However, exact molecular mechanism of synapse dysfunction is largely unknown in AD. Therefore, to understand the molecular basis of synapse dysfunction in AD, we conducted a high throughput multi‐omics analysis of synaptosome fraction in AD and cognitively normal postmortem brain samples.MethodSynaptosomes were extracted from healthy control (HC) postmortem brain (n = 14) and AD postmortem brains (n = 27). Next, we performed miRNAs and mRNAs HiSeq analysis on synaptosomal RNAs. We also used HC (n = 10) and AD (n = 10) synaptosome samples for mass spectroscopy proteomic analysis. We conducted the synaptosomal miRNAs and mRNA sequencing and mass spec analysis on the same groups of samples. Further, we conducted a high throughput multi‐comics analysis to understand the molecular interaction of deregulated synapse miRNAs, mRNAs and proteins at AD synapse.ResultMiRNA HiSeq analysis showed the significant deregulation of several miRNAs in synaptosome fraction in AD vs HC. Our study also identified the several novel potential candidate miRNAs those were deregulated in AD vs HC synaptosomes. Similarly, several protein coding genes and novel transcript were also found to be deregulated in AD vs HC synaptosomes. Further, mass spec analysis showed significant deregulation of several synaptic proteins in AD vs HC synaptosomes. Further, to understand the molecular interaction of synapse miRNAs‐mRNA‐proteins and their deregulation in AD, we conducted high throughput multi‐Omics analysis. Study revealed the involvement of omics targets in several biological process and molecular function such as signal transduction, protein binding, GABAergic synapse and synaptic vesicle cycle etc.ConclusionOur study unveiled the synapse centered novel omics candidates those could be potential therapeutic targets for synapse dysfunction in AD.